Table 2.
Subgroup analysis of the anti-HCV pooled prevalence estimation in Ethiopia, 2020.
| Predictor variables | Variable category | Included studies | ES (95% CI) | I 2 % | p value |
|---|---|---|---|---|---|
| Study group | Blood donor | 19 | 0.01 (0.01, 0.01) | 95.96 | ≤0.001 |
| HIV positive | 6 | 0.04 (0.02, 0.06) | 74.13 | ≤0.001 | |
| Pregnant women | 8 | 0.02 (0.01, 0.05) | 91.83 | ≤0.001 | |
| Mixed groups | 8 | 0.05 (0.02, 0.08) | 93.76 | ≤0.001 | |
| Others | 15 | 0.03 (0.01, 0.06) | 96.48 | ≤0.001 | |
|
| |||||
| Risk of bias | Low | 32 | 0.02 (0.01, 0.02) | 95.88 | ≤0.001 |
| Moderate | 16 | 0.03 (0.01, 0.04) | 98.56 | ≤0.001 | |
| High | 9 | 0.05 (0.02, 0.09) | 95.30 | ≤0.001 | |
|
| |||||
| Region/city | Amhara | 25 | 0.02 (0.01, 0.02) | 97.67 | ≤0.001 |
| Oromia | 6 | 0.02 (0.01, 0.04) | 97.36 | ≤0.001 | |
| SNNPR | 9 | 0.03 (0.01, 0.05) | 96.79 | ≤0.001 | |
| Self-administrative city | 7 | 0.05 (0.02, 0.09) | 95.97 | ≤0.001 | |
| Others | 9 | 0.02 (0.01, 0.03) | 97.96 | ≤0.001 | |
|
| |||||
| Year of publication | 2010–2012 | 3 | 0.02 (0.00, 0.09) | — | — |
| 2013–2015 | 16 | 0.03 (0.01, 0.06) | 98.39 | ≤0.001 | |
| 2016–2020 | 37 | 0.02 (0.01, 0.02) | 96.75 | ≤0.001 | |
|
| |||||
| Sampling techniques | Probability | 19 | 0.02 (0.01, 0.02) | 92.22 | ≤0.001 |
| Entire sampling | 23 | 0.02 (0.01, 0.02) | 98.19 | ≤0.001 | |
| Nonprobability | 7 | 0.02 (0.02, 0.09) | 97.55 | ≤0.001 | |
| Not stated | 7 | 0.05 (0.02, 0.09) | 93.65 | ≤0.001 | |
|
| |||||
| Diagnostic method | ELISA | 37 | 0.02 (0.01, 0.02) | 96.88 | ≤0.001 |
| RDT | 19 | 0.03 (0.02, 0.06) | 95.90 | ≤0.001 | |
ELISA, enzyme-linked immunosorbent assay; RDT, rapid diagnostic test; SNNPR, Southern Nations, Nationalities and Peoples Region.